ForumIAS LATEST
- 16 June | Failed Before Success: AIR 295 Reveals His UPSC Journey | Click Here to Watch →
- 17 June | How to Write High-Scoring Answers in Hindi Literature Optional | Click Here to Watch →
- 18 June | From Setback to Success: Bhavika Chopra's Rise to AIR 25 | Click Here to Watch →
- 19 June | The Rankforge Challenge (FRC/Tapasya): Truth About UPSC & Coaching by Ayush Sinha | Click Here to Watch →
- 20 June | 150+ Cleared UPSC Prelims from Naugaon, Alwar | The FRC Tapasya Success Story | Click Here to Watch →
News: The International Olympic Committee mandated SRY gene screening and banned transgender women and DSD athletes from female categories to ensure fairness and safety.
About SRY Gene Test Screening

- Sex-determining Region Y (SRY) gene test screening is a DNA-based test that detects the presence of the sex-determining region Y gene.
- The SRY gene is a segment of DNA that is almost always on the Y chromosome, signalling the presence of testes/testicles and initiating male sex development by the production of testosterone.
- Developed by: The SRY gene was first discovered in 1990 by Andrew Sinclair.
- Objective: The objective is to protect the female category in elite sports by ensuring that athletes do not have physiological advantages linked to male development.
- Function: The test works by collecting a saliva sample, analyzing DNA for the SRY gene.
- Duration: The analysis process typically takes about one week for the results to be issued and submitted to the relevant international sports body.
- Key features
- Once-in-a-Lifetime Test: The screening is required only once because the SRY gene remains fixed throughout life.
- Indicator of biological development: The SRY gene is treated as a reliable sign of whether an athlete has experienced or will experience male sex development.
- Limited scope of application: It applies only to elite international athletes and not to grassroots or leisure sports.
- Exceptions for rare conditions: Athletes with Complete Androgen Insensitivity Syndrome (CAIS) and other rare XY DSD (Differences in Sex Development) that do not benefit from the anabolic and/or performance-enhancing effects of testosterone would be eligible to compete in female category.



